Investing.com··Chris MarkochCRISPR Therapeutics Rallies on Pipeline Momentum Despite Quarterly Losses
CRISPR stock rallied 12% on pipeline momentum despite quarterly losses and minimal revenue, buoyed by cash reserves and CTX611 candidate progress.
VRTXCRSPrevenue recognitionbiotech pipeline